SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: wolfdog2 who wrote (2746)5/14/1999 2:14:00 PM
From: sam  Read Replies (1) of 10280
 
J and J pulled out of co-marketing agreement, but SEPR will continue with compound on its own. FWIW Interesting comment from the news release: "'We understand that Johnson & Johnson's decision not to market the product was based primarily on the fact that the respiratory market is not expected to be a strategic focus for J& J,' said Timothy J. Barberich, President and Chief Executive Officer."

Though SEPR is obviously going to take a hit here (it already has), the "news" may not be as bad as the plunge might suggest.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News